RG6596 / Roche 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
RG6596 / Roche
NCT05593094: A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors

Recruiting
1
210
Europe, US, RoW
ZN-A-1041 50mg BID, ZN-A-1041 Enteric Capsules, ZN-A-1041 100mg BID, ZN-A-1041 200mg BID, ZN-A-1041 400mg BID, ZN-A-1041 600mg BID, ZN-A-1041 800mg BID, ZN-A-1041 1000mg BID, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1b, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1b, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1b, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1c, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1c, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1c
Suzhou Zanrong Pharma Limited
Advanced Solid Tumors, HER2-positive Breast Cancer
10/25
10/26
ZN-1041-101, NCT04487236: Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors

Recruiting
1
84
RoW
ZN-A-1041 50mg BID, ZN-A-1041 Enteric Capsules, ZN-A-1041 100mg BID, ZN-A-1041 200mg BID, ZN-A-1041 400mg BID, ZN-A-1041 600mg BID, ZN-A-1041 800mg BID, ZN-A-1041 1000mg BID, ZN-A-1041 Level 1 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle, ZN-A-1041 Level 2 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle, ZN-A-1041 MAD +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle, ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First Cycle
Suzhou Zanrong Pharma Limited
Advanced Solid Tumors, HER2-positive Breast Cancer
12/23
06/24

Download Options